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Abstract
The circumsporozoite protein (CSP) plays a key role in malaria sporozoite infection of both mosquito salivary glands and the
vertebrate host. The conserved Regions I and II have been well studied but little is known about the immunogenic central
repeat region and the N-terminal region of the protein. Rodent malaria Plasmodium berghei parasites, in which the
endogenous CS gene has been replaced with the avian Plasmodium gallinaceum CS (PgCS) sequence, develop normally in
the A. stephensi mosquito midgut but the sporozoites are not infectious. We therefore generated P. berghei transgenic
parasites carrying the PgCS gene, in which the repeat region was replaced with the homologous region of P. berghei CS
(PbCS). A further line, in which both the N-terminal region and repeat region were replaced with the homologous regions of
PbCS, was also generated. Introduction of the PbCS repeat region alone, into the PgCS gene, did not rescue sporozoite
species-specific infectivity. However, the introduction of both the PbCS repeat region and the N-terminal region into the
PgCS gene completely rescued infectivity, in both the mosquito vector and the mammalian host. Immunofluorescence
experiments and western blot analysis revealed correct localization and proteolytic processing of CSP in the chimeric
parasites. The results demonstrate, in vivo, that the repeat region of P. berghei CSP, alone, is unable to mediate sporozoite
infectivity in either the mosquito or the mammalian host, but suggest an important role for the N-terminal region in
sporozoite host cell invasion.
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Introduction
The circumsporozoite protein (CSP) is the predominant surface
antigen of Plasmodium sporozoites and is highly immunogenic being
one of the key targets recognised by the host immune system. Pre-
erythrocytic malaria vaccines have been primarily based on CSP
[1,2]. In particular, the central repeat region of P. falciparum CSP,
which contains an immunodominant B cell epitope, represented
the target of the first two vaccine trials [3,4]. Recently, the results
of a phase III trial of the RTS,S vaccine, based on both the repeat
region and T-cell epitopes from the C-terminal region, provided
evidence for protection against both clinical and severe malaria in
African children [5].
CSP performs numerous functions for the sporozoite at different
stages in the life cycle. The protein is first detected at high levels in
the oocyst and has been shown to be vital in the process of
sporogenesis [6,7]. CSP is likely to be important in sporozoite
gliding motility although the precise role that the protein plays in
gliding remains unknown. Antibodies against CSP inhibit gliding
motility [8] and sporozoites leave behind trails of CSP that
correspond to their pattern of movement [9]. CSP has long been
known to be involved in sporozoite infectivity [10,11]. Specifically,
it appears to be important in the binding of the sporozoite to
both mosquito salivary glands [12,13,14] and vertebrate host
hepatocytes [15,16,17].
Comparison of the deduced amino acid sequences of CS
proteins from all species of Plasmodium shows that they have a
similar overall structure. They all contain a central repeat region,
whose amino acid sequence is species specific, and two conserved
regions: a five amino acid sequence called Region I (RI),
immediately upstream of the repeats, and a known cell-adhesive
sequence with similarity to the type I repeat of thrombospondin
called Region II (RII), downstream of the repeat region. CSP has a
canonical glycosylphosphatidylinositol (GPI) anchor addition
sequence in its C-terminus. Much evidence has been gathered
on the functions of the conserved Regions I and II of CSP, as well
as on residues outside of RI and RII, within the N- and C-terminal
portions of the protein, which have been implicated in host
binding [18,19,20,21]. However, little evidence exists to date on
the role of the CSP repeat region in the parasite life cycle.
The RI core is a five amino acid sequence (KLKQP), conserved
in almost all Plasmodium species with the exception of the avian
malaria parasite P. gallinaceum, in which there are two amino acid
changes in the core (NLNQP) (Figure 1). RI has been strongly
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encompassing RI was shown to inhibit binding of both
recombinant CSP and sporozoites to the salivary glands. However,
the RI core alone could not achieve this inhibition and upstream
residues were also required [13,22]. The sequence upstream of RI
contains stretches of positively charged residues which are
implicated, together with RI, in the interaction with liver heparan
sulphate proteoglycans (HSPGs) [19,21]. RI and RII peptides
inhibited P. falciparum CSP (PfCSP) binding to HepG2 cell HSPGs
to a similar extent, suggesting they both contribute to the
interaction [23]. RII is a common motif present in the proteins
of a wide range of organisms and is also found in another
sporozoite surface protein, the thrombospondin-related adhesive
protein (TRAP). It is an 18 amino acid region and part of a larger
type I repeat of human thrombospondin (TSR) domain which acts
as an adhesive module and binds with high affinity to heparin and
certain sulphated glycoconjugates (Figure 1). The rapid and
specific homing to the liver by sporozoites of mammalian
Plasmodium spp. has been ascribed to the interaction between RII
and glycosaminoglycan (GAG) side chains on HSPGs, located on
the basolateral surface of hepatocytes [15,16,23,24,25]. The only
difference between the P. gallinaceum RII and the RII consensus,
present in all Plasmodium species, is a single amino acid substitution,
despite the fact that P. gallinaceum does not infect hepatocytes.
The repeat region is species-specific, immunodominant and
constitutes about one half of the molecule. It contains multiple
copies of tandemly arrayed repeat peptides (Figure 1) and has no
obvious sequence homology to any known protein. The repeats
contain B-cell immunodominant epitopes and antibodies specific
to this region can protect against malaria by blocking sporozoite
invasion of host hepatocytes [26,27]. The function of the CSP
repeat region within the parasite life cycle has so far not been
investigated. However, there are reasons to believe that this large
domain of CSP could perform perhaps multiple functions for the
parasite. The repeat peptide structure might lend itself well to high
avidity interactions with host receptors, for example GAGs which
are composed of repeating sugar units. Multivalency is able to
enhance the affinity of protein-carbohydrate interactions, partic-
ularly those involving GAGs [28], and the repeats could provide
multivalent binding sites. In addition, the species-specific nature of
the region may indicate a role in maintaining the host specificity of
infection.
P. berghei parasites, in which the entire CS gene (PbCS) was
replaced with its P. gallinaceum orthologue, failed to both invade
Figure 1. Schematic representation and alignment of wild type and transgenic P.berghei circumsporozoite proteins. (A) Schematic
representation of the CS proteins present in each of the four transgenic P. berghei parasite lines generated. The corresponding names of the
transgenic parasite lines are shown on the right. PbCS
DHFR parasites carry the wildtype PbCS coding sequence (white boxes, RI and RII indicated with
light and dark green respectively) and, similar to all transgenic lines, contain the T. gondii DHFR drug selectable marker inserted in the CS locus.
PgCS
SX parasites carry the full PgCS coding sequence (grey boxes, RI and RII indicated with light and dark blue respectively), but with the SpeI (S) and
XhoI (X) restriction endonuclease sites inserted on either side of the repeat region. PgCS/Pb
RR parasites contain the PgCS N-terminal and C-terminal
regions (grey boxes) and the PbCS repeat region (white box). PbCS/Pg
CT parasites carry the PbCS N-terminal and repeat regions (white boxes) and the
PgCS C-terminal region (grey box). (B) Alignment of the wild type PbCS and transgenic PgCS
SX and PgCS/Pb
RR amino acid sequences. Shaded boxes
represent areas of amino acid identity. Regions I and II (black lines), the repeat region (blue line) and the SpeI and XhoI restriction sites (red lines) are
labelled. The SpeI and XhoI sites were introduced into the PgCS sequence to mediate exchange of the PgCS repeat region with the PbCS repeat
region.
doi:10.1371/journal.pone.0032524.g001
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development and CSP expression appeared unaffected. P.
gallinaceum is carried by the mosquito vector Aedes aegypti whereas
P. berghei is carried by anopheline vectors. The lack of infectivity
with the PgCS replacement parasites could be due to the inability
of PgCSP to bind to A. stephensi salivary gland receptors and rodent
liver receptors.
To assess whether the repeat region has a role in salivary gland
or vertebrate infectivity, we generated transgenic P. berghei
parasites carrying the PgCS gene, in which the repeat region was
replaced with the PbCS repeat region (Figure 1), in order to
determine if introduction of the wild-type sequence rescues
infectivity. Another parasite line containing the full-length PbCS
N-terminal sequence (up to RI), the PbCS repeat region and the
PgCS C-terminal sequence was also generated and allowed further
analysis of the role of the N- and C-terminal regions (Figure 1).
Results
Generation of transgenic parasites
Transgenic P. berghei parasites were generated that carried
chimeric P. gallinaceum - P. berghei CS genes. In the first transgenic
parasite line, the endogenous PbCS gene was substituted with the
PgCS gene in which the repeat region was replaced with the
homologous region of P. berghei: line PgCS/Pb
RR (Figure 1A). A
second line contained both the N-terminal region and repeat
region of P. berghei, while the C-terminal region was replaced with
the homologous sequence of P. gallinaceum: line PbCS/Pg
CT
(Figure 1A). As controls, we generated: i) a transgenic line carrying
the wild type PbCS gene and the drug selectable marker inserted in
the PbCS locus: line PbCS
DHFR and ii) a transgenic line carrying
the PgCS gene in which the SpeI and XhoI restriction sites had been
introduced on either side of the repeat region: line PgCS
SX
(Figure 1A). A schematic representation and alignment of PbCSP
and the CS proteins expressed in the transgenic parasites, and
their corresponding names, are presented in Figure 1A and 1B
respectively.
The targeting constructs were designed to direct the double
cross-over event between the 1.13 kb sequence of the PbCS 59
untranslated region (UTR) and the 0.85 kb sequence of the PbCS
39 UTR in the linearized plasmid and their corresponding
sequences in the PbCS locus (Figure 2A and Figure S1A). Two
targeting constructs, pPgCS/Pb
RR and pPgCS
SX were then used
to transfect P. berghei wild type (Pbwt) parasites (Figure 2A and
Figure S1A respectively).
In construct pPgCS
SX (Figure S1A), the SpeI and XhoI restriction
sites had been introduced by site-directed mutagenesis into the
PgCS sequence in order to mediate exchange of the PgCS repeat
region with the homologous sequence of P. berghei. The SpeI site
was inserted immediately downstream of the PgCS RI core
sequence, NLNQP (Figure 1). The XhoI restriction site was
inserted after the PgCS repeat region and before RII (Figure 1).
Correct insertion of the construct, to generate the control
transgenic parasite line PgCS
SX (clones 1 and 2), was confirmed
by Southern blot analysis (Figure S1).
A second construct was generated by replacing the PgCS repeat
region in pPgCS
SX with the PbCS repeat region, which had been
amplified from genomic DNA. The resulting construct, pPgCS/
Pb
RR, was then tranfected into Pbwt parasites to create the
transgenic line PgCS/Pb
RR (clones 4 and 5), and correct
integration was confirmed by southern blot (Figure 2).
Other integration events were also observed after transfection
with the pPgCS/Pb
RR vector, as a consequence of cross-over
events that took place between sequences present in the internal
part of the construct and the homologous sequences in the PbCS
locus. This resulted in the generation of two further transgenic
parasite lines, PbCS/Pg
CT and PbCS
DHFR (Figure 3 and Figure
S2). PbCS/Pg
CT clones 3 and 6 originated from cross-over events
at the 0.5 kb PbCS repeat region and the 39 UTR sequence
(Figure 3A). The PbCS/Pg
CT parasite line generated therefore
contained a chimeric CS gene where both the N-terminal
sequence and the repeat region were from P. berghei, while the
C-terminal sequence was from P. gallinaceum, as demonstrated by
Southern blot analysis (Figure 3).
Moreover, just 300 bp of the PbCS 39 UTR, present between
the chimeric CS gene and the TgDHFR/TS cassette in the
construct pPgCS/Pb
RR, was sufficient to direct recombination,
generating the PbCS
DHFR transgenic line (Figure S2A). Double
cross-over recombination, between the two PbCS 39 UTR regions
present in the construct and the homologous regions in the PbCS
locus, resulted in the insertion of only the TgDHFR/TS cassette,
in the 39 UTR region of the PbCS locus, leaving the endogenous
PbCS gene intact. The transgenic PbCS
DHFR clones 9 and 10
generated (Figure S2) were used as a control for any phenotypic
effects arising from the presence of the selectable marker cassette
within the CS locus.
The insertion events described, and the presence of the correct
CS gene sequences in the transgenic parasites lines, was further
confirmed by sequencing the CS genes, which had been PCR
amplified from genomic DNA.
Development of the transgenic parasites in the mosquito
vector
Blood stage parasites from all transgenic lines replicated
normally in mice and in vitro generated gametocytes that developed
into fertile gametes. The development of the transgenic parasites
in the mosquito was monitored in Anopheles stephensi fed on infected
mice. Mosquito midguts infected with each of the transgenic
clones, and dissected at 14 and 18 days post-infection (p.i.),
revealed normal oocyst development compared to mosquitoes
infected with Pbwt parasites. All transgenic oocysts had the same
morphology as Pbwt oocysts. Interestingly, melanisation (observed
in mosquitoes infected with PgCS-replacement P. berghei parasites
[29]) was only seen in midguts infected with transgenic lines
containing PgCS sequences. However, it occurred with a very low
frequency both in terms of the proportion of infected midguts and
also the number of melanised oocysts per midgut.
Midguts dissected on day 14 p.i. showed no significant
differences in oocyst and sporozoite numbers between any of the
transgenic parasite lines and Pbwt parasites (Table 1), indicating
that both heterologous PgCSP and the chimeric proteins function
normally during sporozoite ontogeny in the mosquito vector A.
stephensi. However, at day 21 p.i., PgCS
SX parasites showed a
significant reduction in the number of salivary gland sporozoites
compared to both Pbwt and PbCS
DHFR control parasites, similar
to the results previously reported for mosquitoes infected with
PgCS-replacement P. berghei parasites [29]. Likewise, PgCS/Pb
RR
parasites showed a striking and significant reduction in salivary
gland sporozoites compared to Pbwt and PbCS
DHFR parasites
(Table 1). Furthermore, no significant difference was observed
between PgCS
SX and PgCS/Pb
RR clone 4 (p.0.09), although the
difference between PgCS
SX and PgCS/Pb
RR clone 5 was
significant (p,0.03). However, this result for PgCS/Pb
RR clone
5 may have been due to contaminating hemolymph sporozoites or
a greater number of sporozoites adhering to the outside of the
glands.
The low numbers of salivary gland sporozoites in mosquitoes
infected with PgCS/Pb
RR parasites suggests that the replacement
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RR parasite lines. (A) Schematic representation of (i) the PgCS/Pb
RR
targeting construct, (ii) the wt PbCS locus and (iii) the targeted locus after recombination between the PbCS 59UTR and 39UTR sequences. The
vertically dashed box indicates the 1.13 kb 59UTR sequence used in the construct and the horizontally dashed boxes indicate the 0.3 kb and 0.85 kb
39UTR sequences between which the TgDHFR-TS selectable marker cassette (light grey) was inserted in the construct. The PgCS/Pb
RR chimeric gene
contains the PgCS N- and C-terminal regions (dark grey boxes) and the PbCS repeat region (white box) flanked by the SpeI( S) and XhoI( X) sites. In the
wt PbCS locus the white box indicates the full PbCS gene. Thick black lines indicate the probes used in southern blots. E: EcoRV site. (B) Southern blot
of EcoRV/SpeI (E/S) and EcoRV/XhoI (E/X) digested genomic DNA from Pbwt parasites and transgenic PgCS/Pb
RR parasites (clones 4 and 5), hybridised
with the PbCS 39UTR probe. Two bands of 4.0 and 1.5 kb were present in Pbwt DNA in both digestions. E/S digested DNA from the PgCS/Pb
RR clones
revealed two bands of 1.1 and 2.0 kb, while E/X digested DNA revealed two bands of 0.6 and 2.0 kb, demonstrating the replacement of the
endogenous PbCS gene with the targeted construct. (C) The same membrane was then hybridised with the PgCS N-terminal probe (PgCS-Nt),
encompassing the entire N-terminal region of PgCS. No band was present in Pbwt DNA. However, a band of 3.1 kb or 3.6 kb was present in the E/S or
E/X digested transgenic DNA, respectively.
doi:10.1371/journal.pone.0032524.g002
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CT parasite lines. (A) Schematic representation of (i) the PgCS/Pb
RR
targeting construct, (ii) the wt PbCS locus and (iii) the targeted locus after recombination between the PbCS repeat region (white box) and the PbCS
39UTR (horizontally dashed box). The PbCS/Pg
CT chimeric gene contains both the PbCS N- terminal and repeat regions (white boxes) and the PgCS C-
terminal region (dark grey box). The light grey box indicates the TgDHFR-TS selectable marker cassette. Thick black lines indicate the probes used in
southern blots. E=EcoRV site, S=SpeI site and X=XhoI site. (B) Southern blot of EcoRV/SpeI (E/S) and EcoRV/XhoI (E/X) digested genomic DNA from
Pbwt parasites, transgenic PgCS/Pb
RR clone 4 parasites and PbCS/Pg
CT parasites (clones 3 and 6), hybridised with the PbCS 39UTR probe. PgCS/Pb
RR
parasites acted as a control for the presence of both the SpeI and XhoI sites in the CS chimeric gene. Both PbCS/Pg
CT clones contained a gene with
the XhoI site but lacked the SpeI site, as demonstrated by the presence of the 4.0 and 2.0 kb bands after E/S digestion and the 2.0 and 0.6 kb bands
after E/X digestion, indicating the 59 cross-over event had occurred between the repeat regions. (C) Southern blot of E/S and E/X digested genomic
DNA, hybridised with the PbCS N-terminal region probe. A band of 4.0 kb was detected in both the Pbwt DNA and E/S digested DNA from the PbCS/
Pg
CT clones, demonstrating the presence of the PbCS N-terminal sequence in the transgenic parasites. Genomic DNA from the PbCS/Pg
CT clones,
digested with E/X, revealed a band of 3.5 kb, indicating the presence of the XhoI site. No bands were visible in PgCS/Pb
RR transgenic parasite DNA
due to the absence of the PbCS N-terminal sequence.
doi:10.1371/journal.pone.0032524.g003
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is not sufficient to rescue salivary gland invasion. In contrast, the
PbCS/Pg
CT transgenic parasites invaded the mosquito salivary
glands normally. These parasites contain only the C-terminal
sequence of PgCSP, which appears to function normally in A.
stephensi salivary gland infection. The results suggest that the N-
terminal region plays an important role in salivary gland infection,
although it is still possible that repeat region residues co-operate
with N-terminal residues in infectivity. This is in agreement with
previous studies, which used recombinant N-terminal peptides to
demonstrate a role for the region in salivary gland binding [13,22].
Infectivity of the transgenic sporozoites for the
vertebrate host
To determine the infectivity of the transgenic parasites for the
vertebrate host, salivary gland and midgut sporozoites, collected
21 days p.i., were injected intravenously into C57BL/6 mice. All
mice injected with Pbwt salivary gland sporozoites developed a
parasitaemia, with a pre-patent period ranging from 3.5 to 4.6
days for mice injected with 5,000 and 1,000 sporozoites
respectively (Table 2). Interestingly, for the PbCS
DHFR transgenic
parasites, only injection with 5,000 sporozoites resulted in a 100%
infection rate, and the pre-patent period was longer, ranging from
5.3 to 6.5 days after injection of 5,000 or 1,000 PbCS
DHFR
sporozoites, respectively. A 1 day delay in the pre-patent period
indicates a 90% decrease in the infective inoculum [30]. This
difference in infectivity between Pbwt and PbCS
DHFR parasites
suggests a moderate effect on vertebrate host infection due to the
presence of the selectable marker cassette in the CS locus.
Mice injected with 5,000 sporozoites, from salivary gland
preparations of either PgCS
SX or PgCS/Pb
RR infected mosqui-
toes, did not develop a parasitaemia, demonstrating that the
replacement of the PgCS repeat region with the homologous
wildtype PbCS repeat region is also unable to rescue vertebrate
infectivity.
The PbCS/Pg
CT clones had very similar infection rates and
pre-patent periods compared to the PbCS
DHFR clones, indicating
that the N-terminal sequence is also important for vertebrate
infectivity. Moreover, the PgCSP C-terminal sequence appears to
function efficiently in vertebrate infectivity, despite the fact that
only 39 out of the 85 amino acids in the C-terminus of CSP are
conserved between P. berghei and P. gallinaceum, including 10 of the
18 Region II residues (Figure 1B).
We also investigated the infectivity of midgut sporozoites in
C57BL/6 mice. Only one out of two mice injected with
500,000 Pbwt sporozoites became parasitaemic, with a pre-patent
period of 6.0 days (Table 3). This is consistent with the known
lesser infectivity of midgut sporozoites compared to salivary gland
sporozoites [31]. A pre-patent period between 7.0 and 8.0 days
was observed after injection of 500,000 PbCS
DHFR or PbCS/Pg
CT
sporozoites, demonstrating a similar delay compared to Pbwt
Table 1. Transgenic parasite development in the Anopheles stephensi mosquito vector.
Parasite Midgut oocysts
Midgut
sporozoites Sporozoites/oocyst
Salivary gland
sporozoites
Salivary gland sporozoites/
oocyst
Pbwt 182642 12,174619,070 63679 28,41268,167 134614
PbCS
DHFR cl9 1956105 26,021640,551 1446217 25,62665,185 154670
PbCS
DHFR cl10 190647 15,37766,451 89653 14,44764,503 83640
PgCS
SX cl1 189693 6,44765,221 36627 2976336
a 262
PgCS/Pb
RR cl4 202666 14,84466,773 86669 9226697
a 665
PgCS/Pb
RR cl5 194632 13,89268,871 68637 1,2766300
a,b 763
PbCS/Pg
CT cl3 207677 33,821632,294 2406311 15,77963,832 80617
PbCS/Pg
CT cl6 248655 32,520622,484 133699 18,29168,231 78647
aSignificant difference compared to Pbwt and PbCS
DHFR transgenic parasites; p,0.01.
bSignificant difference compared to PgCS
SX;p ,0.03.
A. stephensi mosquitoes were fed on mice infected with one of the transgenic clones or Pbwt parasites. Values represent the mean 6 S.D. of at least three independent
experiments, each with a minimum of 50 mosquitoes.
doi:10.1371/journal.pone.0032524.t001
Table 2. Infectivity of salivary gland sporozoites for the
vertebrate host.
Parasite
Sporozoites
injected
Mice
infected
Pre-patent
period
a
Pbwt 1,000 5/5 4.6
3,000 3/3 4.0
5,000 3/3 3.5
PbCS
DHFR cl9 1,000 1/6 6.0
3,000 4/6 6.0
5,000 4/4 5.5
PbCS
DHFR cl10 1,000 2/4 6.5
3,000 2/4 6.0
5,000 3/3 5.3
PgCS
SX cl1 5,000 0/3 -
PgCS/Pb
RR cl4 5,000 0/5 -
PgCS/Pb
RR cl5 5,000 0/5 -
PbCS/Pg
CT cl3 1,000 0/3 -
3,000 3/4 5.7
5,000 5/6 5.5
PbCS/Pg
CT cl6 1,000 1/3 6.0
3,000 3/4 6.0
5,000 4/5 5.5
aPre-patent period is the number of days between injection and first
appearance of the parasites in the peripheral blood.
C57BL/6 mice were injected intravenously with different numbers of Pbwt or
transgenic sporozoites collected on day 21 p.i. from A. stephensi salivary gland
preparations. The number of mice that became infected and the pre-patent
period were both recorded.
doi:10.1371/journal.pone.0032524.t002
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preparation sporozoites. PgCS/Pb
RR and PgCS
SX midgut sporo-
zoites never infected mice (Table 3).
CSP expression in transgenic parasite lines
Immunofluorescence assays (IFA) were carried out to analyse
both CSP expression and gliding motility of midgut sporozoites,
since PgCS/Pb
RR and PgCS
SX transgenic parasites do not appear
to invade the salivary glands. Freshly dissected sporozoites were
spotted onto a glass slide and either left at room temperature (RT)
or placed at 37uC for 30 minutes to induce gliding motility [32].
The parasites were then allowed to react with either a monoclonal
antibody directed against the PbCSP repeat region, a polyclonal
antibody directed against the PgCSP N-terminal region, or a
polyclonal antibody directed against the PgCSP repeat region
(Figures 4 and S3).
Sporozoites from each of the transgenic clones, except PgCS
SX
and PgCS replacement parasites, showed a clear and uniform
surface staining when incubated with the antibody against the
PbCSP repeat region (Figure 4), similar to the staining observed
for Pbwt sporozoites [33]. Although midgut sporozoites display
limited gliding motility compared to salivary gland sporozoites,
after incubation at 37uC with the PbCSP repeat region antibody,
trails could be observed with Pbwt, PbCS
DHFR, PbCS/Pg
CT and
PgCS/Pb
RR parasites at a similar frequency, between 5 and 10%
(Figure S3). However, the trails were extremely variable in shape
and length and only very rarely were circular trails (,1% of total
trails), similar to those seen for salivary gland sporozoites, observed
(Figure S4). These results demonstrated that the presence of
lengthy heterologous PgCS sequences in the chimeric CS genes
does not significantly modify the surface expression of the proteins
or the parasites’ gliding motility. Therefore, the inability of the
PgCS/Pb
RR parasites to infect the mosquito salivary glands or the
vertebrate host does not appear to be due to incorrect CSP surface
expression or motility.
Interestingly, analysis of the PgCS/Pb
RR, PgCS
SX and PgCS
replacement parasites with the PgCSP N-terminal region antise-
rum revealed the localization of the CSP to be mainly
intracellular, throughout the cytosol (Figure 4). In contrast,
PgCS/Pb
RR parasites, when analysed with the antibody against
the PbCSP repeat region, displayed clear surface CSP expression
(Figure 4) [33]. Similarly, PgCS
SX and PgCS replacement
sporozoites, incubated with a serum against the PgCSP repeat
region, revealed normal surface staining (Figure 4), and also the
presence of clumps of immunoreactive material either outside the
parasite body or in proximity to its surface, following incubation at
37uC (Figure S3) [29], indicating that the introduction of the two
restriction endonuclease sites in the PgCS sequence had no obvious
effect on protein expression and release.
These IFA results are in agreement with recent data that report
the absence of the N-terminal CSP sequence on the surface of P.
berghei oocyst sporozoites [34]. The two antibodies are therefore
reacting with different processed forms of CSP: the repeat region
antibodies with a lower molecular weight (MW) form, lacking the
N-terminal region and associated with the surface of the
sporozoite, and the PgCSP N-terminal region serum with a higher
MW form present in the cytoplasm.
Salivary gland sporozoites from Pbwt, PbCS
DHFR and PbCS/
Pg
CT infected mosquitoes, incubated with the PbCSP repeat
region antibody, displayed a regular CSP surface expression and
the characteristic circular gliding motility (Figure S4), with no
differences observed either in the frequency of motile sporozoites
or the percentage forming trails of at least one complete loop.
CSP processing in transgenic parasite lines
We investigated the expression and processing of CSP in the
transgenic parasites by Western blot analysis of midgut sporozoite
lysates collected 18 days p.i.. The PbCSP repeat region antibody
revealed both the high and the low MW CSP forms in PbCS
DHFR,
PbCS/Pg
CT and PgCS/Pb
RR transgenic parasites (Figure 5)
[11,35]. A ladder of bands, weaker in intensity and ranging in
size between ,30 and 46 kDa, was also present and has previously
been described [36,37]. These results demonstrate that the CSPs
in the transgenic parasite lines are expressed and processed
similarly to CSP in Pbwt parasites.
Incubation with the PgCSP N-terminal region antiserum
revealed only the high MW form, corresponding to the CS
precursor, in the PgCS/Pb
RR and PgCS
SX parasite lines, in
agreement with N-terminal region cleavage to yield the mature,
processed form of CSP, containing the repeat region and C-
terminal region. The band present in the PgCS/Pb
RR parasites
appears to be slightly bigger than the expected ,54 kDa band
(revealed after incubation with the PbCSP repeat region antibody).
This difference in size is likely due to the fact that the PbCSP
repeat region is extremely proline rich and this has been shown to
be responsible for anomalous migration patterns of proteins in
SDS-PAGE [38].
Discussion
The aim of this work was to investigate the role of the CSP
repeat region and the amino terminal region in the recognition of
species-specific vector and host receptors. In previous studies,
transgenic P. berghei parasite lines, in which either the entire
endogenous CS gene or the repeat region was replaced with the P.
falciparum orthologous sequence, both showed a ten fold reduction
in A. stephensi salivary gland invasion [27,29], suggesting a
functional role of the repeat sequence in the recognition of
species-specific host receptors. Our results indicate that the repeat
region, on its own, is unlikely to represent the sporozoite species-
specific salivary gland or hepatocyte ligand, because the
replacement of the PgCS repeat region with the PbCS repeat
region in the PgCS/Pb
RR transgenic parasites doesn’t rescue
Table 3. Infectivity of midgut sporozoites for the vertebrate
host.
Parasite
Sporozoites
injected Mice infected
Pre-patent
period
a
Pbwt 100,000 0/3 -
300,000 2/4 7.0
500,000 1/2 6.0
PbCS
DHFR cl9 500,000 1/4 8.0
PbCS
DHFR cl10 500,000 1/2 7.0
PgCS
SX cl1 500,000 0/5 -
PgCS/Pb
RR cl4 500,000 0/4 -
PgCS/Pb
RR cl5 500,000 0/4 -
PbCS/Pg
CT cl3 500,000 1/5 8.0
PbCS/Pg
CT cl6 500,000 2/5 7.0
aPre-patent period is the number of days between injection and first
appearance of the parasites in the peripheral blood.
C57BL/6 mice were injected intravenously with Pbwt or transgenic midgut
sporozoites collected on day 21 p.i.. The number of mice that became infected
and the pre-patent period were both recorded.
doi:10.1371/journal.pone.0032524.t003
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vertebrate hepatocytes. However, it is still possible that sequences
in the N-terminal region and repeat region cooperate in, and are
both required for, sporozoite infectivity.
The P. berghei transgenic parasites bearing a chimeric CSP
displaying the P. falciparum CS repeat region, also had the RI motif
and 14 residues upstream (RI-plus) exchanged with those of P.
falciparum [27]. The change in either the repeat region or RI-plus
could have been responsible for the 10-fold decrease in salivary
gland invasion observed with these parasites. Although the RI core
is the same between the two species (KLKQP), RI-plus differs
between P. berghei and P. falciparum. In both P. falciparum and P.
berghei nine of the fourteen residues are charged, indicating that the
regions might be involved in interactions with host receptors.
Nevertheless, it is possible that the repeat region has a function in
infectivity acting in concert with other CSP regions. The CSP
repeat region may fulfill a structural role, with the repeats from
neighboring CSP molecules interlocking to form a rigid sheath
surrounding the parasite [39]. Proline-rich tandem repeats
generally form extended structures and flexible regions in proteins,
and have been shown to function both as structural elements and
in binding processes [40].
PbCS/Pg
CT parasites, containing both the PbCS N-terminal and
repeat regions, were not impaired in salivary gland or vertebrate
infectivity, pointing to a role for the N-terminal region in infection.
Indeed, sera against the P. falciparum and P. berghei CSP N-terminal
regions have been shown to inhibit sporozoite invasion of
hepatocytes in vitro and HepG2 cells [41]. In previous investiga-
tions, a role in salivary gland infectivity was implied based on
binding inhibition experiments, in which specific peptides were
Figure 4. Sporozoite CSP expression. Confocal immunofluorescence microphotographs of transgenic midgut sporozoites incubated at room
temperature and developed with either a monoclonal antibody directed against the PbCSP repeat region (Pb-RR), a serum directed against the PgCSP
N-terminal region (Pg-Nt), or a serum directed against the PgCSP repeat region (Pg-RR). Antibodies against the PbCSP and PgCSP repeat regions
showed surface expression of the CSPs, whereas antibody against the PgCSP N-terminal region revealed mainly an intracellular pattern of expression.
doi:10.1371/journal.pone.0032524.g004
Figure 5. Western blot analysis of CSP expression and
processing in transgenic midgut sporozoites 18 days post-
infection. CSP expression was revealed by incubation with either a
monoclonal antibody directed against the PbCSP repeat region (PbCS-
RR) or a serum directed against the PgCSP N-terminal region (PgCS-Nt).
As a control, midgut lysates from uninfected mosquitoes were also
analysed. Antibody against the PbCSP repeat region reveals a higher
molecular weight precursor polypeptide and a lower molecular weight
processed polypeptide. A ladder of degradation products is also visible.
Antibody against the PgCSP N-terminal region reveals only the higher
molecular weight protein.
doi:10.1371/journal.pone.0032524.g005
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binding to the glands [13,22]. However, the results of peptide
inhibition studies can be due to steric hindrance. Therefore, gene
targeting provides a more reliable system for determining the
function of protein domains.
IFA analysis with a serum directed against the PgCSP N-
terminal region appeared to localise the PgCS/Pb
RR and PgCS
SX
proteins mainly to the intracellular compartment, in contrast to
antibodies against the PbCSP and PgCSP repeat regions, which
revealed fluorescence at the surface of transgenic sporozoites
(Figure 4). The results indicate that two forms of CSP are present
in our transgenic lines: a full length protein localised intracellularly
and a processed form, lacking the N-terminal region, and
expressed uniformly on the sporozoite surface. This suggests
possibly an intracellular site of CSP processing or alternatively, the
protein may be cleaved either during its release from the apical
organelles, before translocation onto the sporozoite surface, or
after contact with target cells. Contradictory results support both
intracellular [35,42,43] and surface [44,45] sites of CSP cleavage.
In Toxoplasma gondii, the N-terminal region of the adhesive protein,
MIC2, is trimmed prior to secretion [46]. Another T. gondii
protein, MIC3, which is re-localised to the surface of the parasite
during invasion, is synthesised with an N-terminal propeptide that
is cleaved during trafficking to the microneme. The processing was
shown to be required for the protein to function as an adhesin [47]
and it is possible that a similar mechanism operates in Plasmodium
CSP.
Western blot analysis demonstrated that at least a large part of
the N-terminal region is cleaved from the precursor polypeptide in
each of the transgenic lines. Furthermore, data suggests that the
protease that mediates CSP cleavage is parasite derived rather
than host derived [45], which is compatible with an intracellular
site of processing. The protease may therefore differ between P.
berghei and P. gallinaceum parasites, which could in turn affect the
correct processing of the transgenic CS proteins. However, the
results indicate that the P. berghei protease is able to similarly cleave
PbCSP and the chimeric CS proteins.
Our results demonstrate that the N-terminal region of CSP is
important for infectivity, which suggests that at least part of this
sequence is likely to be present on the sporozoite surface, possibly
acting as a ligand for host receptors. This observation is partially in
agreement with the recent results from Coppi et al. [34], in which
they identify a higher MW CSP on the surface of the sporozoites.
We have tried to determine the precise cleavage site in our
transgenic lines by sequencing the low MW form of CSP, however
we were unable to obtain enough material.
Recent results indicate that RI plays a critical role in CSP
processing either because it is required for efficient cleavage or
because it contains the cleavage site [34]. RI in P. gallinaceum
(NLNQP) differs from mammalian Plasmodium spp. RI (KLKQP)
and yet the PgCS/Pb
RR protein is still processed, probably by the
same proteolytic enzyme. Both the high and low MW CSP bands
of the PgCS/Pb
RR parasites run slightly higher compared to the
equivalent bands of the PbCS/Pg
CT parasites in Western blot
analysis (Figure 5). This is in part due to the fact that the chimeric
proteins have different sizes: PgCS/Pb
RR and PbCS/Pg
CT contain
382 and 347 amino acids respectively. If the cleavage site is located
at RI, one would expect the low MW bands from these two
parasite lines to be the same size, since the processed CSPs in both
these lines would contain the PbCS repeat region and the PgCS C-
terminal region. Only the high MW bands, representing the
precursor polypeptides, would differ in size. However, in our
Western blot analysis, both the high and low MW bands from the
PgCS/Pb
RR parasites appear to have larger MWs compared to
the equivalent bands in the PbCS/Pg
CT parasites. This could be
explained if the cleavage site is located upstream of RI, in the N-
terminal region: an extra 25 amino acids are present just upstream
of RI in the PgCSP sequence compared to the PbCSP sequence
(Figure 1A), and this could explain the greater MW of the
processed protein in PgCS/Pb
RR parasites compared to that of
PbCS/Pg
CT parasites.
The sequence just upstream of RI contains a stretch of charged
residues that, if included in the processed form of the protein, may
act as a ligand. A peptide from PfCSP, spanning a region just
upstream of RI (AA 93 to 113), was found to serve as a ligand for
both hepatocytes [21] and salivary glands [13,22]. Importantly,
recognition of the short N-terminal peptide (PfCSP65–110) by sera
from children living in a malaria-endemic region was associated
with protection from disease [41]. The sequence of both RI and
RI-plus varies considerably between P. berghei and P. gallinaceum
(Figure 1A). In PbCSP, RI and the first 25 residues upstream of it
contain 14 charged residues compared to the corresponding
PgCSP sequence that contains only seven charged residues and
this may explain the difference in infectivity observed between the
PgCS/Pb
RR and the PbCS/Pg
CT parasites.
The numerous investigations into the functions of CSP’s
conserved motifs, RI and RII, have by no means led to a broad
understanding of CSP’s interactions during host infection. More
recent work on CSP has focused on the N-terminal region of the
protein [41] and the stretches of positively charged residues found
throughout this region [19,22]. The present investigation high-
lights, in vivo, a role for N-terminal residues in sporozoite infectivity
in both the vertebrate and invertebrate hosts. These parasites
could also provide a valuable rodent model to investigate the
emerging role of the CSP N-terminal region in the induction of
protective immune responses.
Materials and Methods
Ethics statement
Animal work conducted at Imperial College was performed
according to UK Home Office Regulations and approved under
Home Office License PPL 70/6453. Studies carried out at Perugia
University have been performed according to the D.L 27 January
1992, n. 116, Italian legislation, and approved under Ethics
Committee Licence n. PR 0161.
DNA constructs
The targeting constructs pPgCS
SX, pPgCS/Pb
RR and
pPbCS
DHFR generated in this study contained the following
structural elements: (i) the first 1,130 nucleotides of the PbCS 59
UTR sequence immediately upstream of the start codon; (ii)
PgCS, PbCS or a chimeric form of the CS coding sequence and
(iii) the first 1,150 nucleotides of the PbCS 39 UTR sequence
immediately downstream of its stop codon, in which the T. gondii
dihydrofolate reductase/thymidylate synthase (TgDHFR/TS)
drug selectable marker cassette (5,150 bp) was inserted at its
HindIII site.
All three constructs were generated from a targeting construct,
pPgCS, already available in our laboratory which contains the full
PgCS coding sequence [29]. The SpeI and XhoI sites were
introduced on either side of the PgCS repeat region by PCR
based site-directed mutagenesis. Primers used to introduce SpeI
were: For1 59-GAGAAAATGTTGTGAATCTTAATCAACCA-
ACTAGTGTTGGAGGAAATGGTGGTGTTCAACCTGCT-
G-39 (SpeI is underlined) and Rev1 complementary to the forward
primer. Primers used to introduce XhoI were: For2 59-CTGAA-
GAAGAAAAGGAGGATGAACCAATACCAGATCTCGAGC-
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is underlined) and Rev2 complementary to the forward primer.
The 1.02 kb PbCS gene was amplified from P. berghei genomic
DNA (Anka strain, clone 2.34) and sequenced. Forward and reverse
primers were designed to amplify the PbCS repeat region from this
sequence, introducing the SpeI and XhoI sites at either end of the
repeat region (Spefor 59-TAATAATAAATTGAAACAACCAAC-
TAGTCCACCACCACCAAACCCAAATG-39 (SpeI is under-
lined) and XhoRev 59-CCGCTCGAGGATATAAGAATCGTCA-
TTATTATTATTTTTGTTATTG-39 (XhoI is underlined)). The
PgCS repeat region was then replaced with the PbCS repeat region,
via SpeIa n dXhoI digestions. Sequencing analysis and alignment
with the wild type P. berghei (GenBank: M14145) or P. gallinaceum
(GenBank: 65959) sequences confirmed the correct CS genes
inserted in each construct.
Parasite transformation
Plasmids pPgCS
SX and pPgCS/Pb
RR were digested with ApaI
to release the ,8.6 kb targeting insert from the plasmid backbone
and the insert was purified by gel electrophoresis. Purified
schizonts of the P. berghei ANKA strain (clone 2.34) were
transformed with 5 mg of targeting DNA using an Amaxa Gene
Pulser set at program U33. Mutant parasites were obtained by the
standard method of drug (pyrimethamine) selection in mice [48].
Pyrimethamine resistant parasites were subsequently cloned by
limiting dilution.
Southern blot analysis
Genomic DNA was isolated from parasites as previously
described [33]. 1–3 mg of genomic DNA was digested with EcoRV
alone or in combination with either SpeIo rXhoI, separated on an
agarose gel and blotted onto a nylon Hybond-N+ membrane
(Amersham). The following DNA fragments were used as probes:
(a) the 1.15 kb fragment of the PbCS 39 UTR from the targeting
constructs, (b) the entire N-terminal sequence of the PbCS coding
region, (c) the entire N-terminal sequence of the PgCS coding
region and (d) a 520 bp fragment amplified from the TgDHFR/TS
coding sequence with the primers TgFor123 (59-AGAGGGG-
CATCGGCATCAAC-39) and TgRev124 (59-TTGAAAGAATG-
TCATCTCCG-39). All hybridization experiments were carried
out as previously described [33,49].
Sequencing of genomic DNA
The primers PbCS59UTR39F( 5 9-CCCTCACATAAGACA-
ATCC-39) and PbCS39UTR59R( 5 9-GTTTACACACGTCA-
TATGTATG-39), which anneal to the 59 and 39 UTR sequences
of the CS locus, were used to amplify the full length CS gene from
blood stage transgenic parasite genomic DNA, isolated from
sporozoite-infected mice where possible. The PCR products were
then sequenced directly (MWG-Biotech).
Parasite development in the mosquito
Female mosquitoes (4–6 days old) of A. stephensi (strain sd500),
were fed for 30 minutes on either wild type (wt) or transgenic
parasite infected BALB/c mice (six- to eight-week-old female
Balb/c from Harlan Sprague) with a parasitaemia ranging from
5% to 10%. Mosquitoes were dissected at days 14 and 21 post
infection (p.i.) to determine the presence of oocysts and the
number of parasites in the midguts and salivary glands.
Parasite infectivity in mice
Midgut and salivary gland sporozoites were diluted with RPMI
and intravenously (i.v.) injected into C57BL/6 mice (six- to
eight-week-old female C57BL/6 from Charles River) in order to
assess vertebrate infectivity. After sporozoite injection, blood
samples were withdrawn from the tails at regular intervals up to
15 days p.i. and a minimum of 10,000 erythrocytes were examined
on Giemsa stained blood smears. The pre-patent period was
determined as the number of days between sporozoite injection
and when parasites were first detected in the blood.
Western blot analysis
Total proteins were extracted from infected (day 18 p.i.) and
uninfected A. stephensi mosquito midguts using reducing sample
buffer and separated on a 12% gel by SDS-PAGE. Blots were
incubated for 1 hour at RT with the appropriate primary
antibody: either a 1:200 dilution of the monoclonal antibody
3D11 raised in mice against the PbCSP repeat region [11] or a
1:200 dilution of a mouse serum raised against the PgCSP N-
terminal region (a gift from Dr. Dharmendar Rathore), then
developed with the enhanced chemiluminescence detection
system, according to the manufacturer’s instructions (Amersham
Pharmacia).
Immunofluorescence analysis
Freshly dissected sporozoites collected at day 21 p.i. from
mosquito midguts and salivary glands were diluted in RPMI 1640
and spotted onto multiwell microscope slides. The slides were
either incubated at 37uC, to induce sporozoite gliding [32], or at
RT for 30 minutes. Parasites were fixed with 1% formaldehyde in
16PBS and blocked with 1% BSA in 16PBS for 30 minutes at
RT. The slides were then incubated with one of three primary
antibodies: the monoclonal antibody against the PbCSP repeat
region [11], the serum against the PgCSP N-terminal region or a
1:1000 dilution of a rabbit serum raised against the PgCSP repeat
region. Antibody bound to the parasites or their trails was revealed
by incubation with fluorescein isothiocyanate (FITC)-conjugated
secondary antibody (Becton Dickinson). Analysis of expression was
carried out using a Leica TCS SP 2 confocal microscope.
Supporting Information
Figure S1 Generation and southern blot analysis of
transgenic PgCS
SX parasite lines. (A) Schematic representa-
tion of (i) the PgCS
SX targeting construct, (ii) the wt PbCS locus
and (iii) the targeted locus after recombination between the PbCS
59UTR and 39UTR sequences. The vertically dashed box
indicates the 1.13 kb 59UTR sequence used in the construct and
the horizontally dashed boxes indicate the 0.3 kb and 0.85 kb
39UTR sequences between which the TgDHFR/TS selectable
marker cassette (light grey) was inserted in the construct. The
PgCS
SX gene contains the full PgCS coding sequence (dark grey)
into which the SpeI( S) and XhoI( X) sites were inserted on either
side of the repeat region. Thick black lines indicate the probes used
in southern blots. E=EcoRV. (B) Southern blot of EcoRV digested
genomic DNA from Pbwt parasites and PgCS-replacement
parasites (clone 14, [29]), that acted as negative and positive
controls respectively, and transgenic PgCS
SX parasites (clones 1
and 2). The blot was first hybridised with the PbCS 39UTR probe,
containing the full 1.15 kb fragment of the PbCS 39UTR sequence
present in the targeting construct. The 39UTR probe hybridised
with bands of 4.0 and 1.5 kb in digested Pbwt DNA and with
bands of 4.2 and 2.0 kb in the transgenic parasite DNA. The size
shift from 4.0 to 4.2 kb is due to the longer PgCS coding sequence.
The 2.0 kb band indicates the presence of the TgDHFR/TS
cassette in the PbCS locus. The membrane was also hybridized
with probes encompassing the TgDHFR/TS gene (C), the PbCS
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a band of 4.6 kb only in transgenic DNA (C). The PbCS probe
revealed the 4.0 kb band only in the Pbwt DNA (D) while the PgCS
probe bound to the correct 4.2 kb band only in the transgenic
parasite DNA (E).
(TIF)
Figure S2 Generation and southern blot analysis of
transgenic PbCS
DHFR parasite lines. (A) Schematic repre-
sentation of (i) the PgCS/Pb
RR targeting construct, (ii) the wt PbCS
locus and (iii) the targeted locus after recombination between the
two PbCS 39 UTR sequences (horizontally dashed boxes) flanking
the TgDHFR-TS selectable marker cassette (light grey box). The
targeted locus therefore carried the endogenous wt PbCS gene
(white box) and, inserted in the 39UTR, the TgDHFR-TS
selectable marker cassette. Thick black lines indicate the probes
used in southern blots. E: EcoRV site, S: SpeI site and X: XhoI site.
(B) Southern blot of EcoRV/SpeI digested genomic DNA from
Pbwt parasites and transgenic PbCS
DHFR parasites (clones 9 and
10), hybridised with the PbCS 39 UTR probe. (C) Southern blot of
EcoRV/XhoI digested genomic DNA hybridised with the PbCS N-
terminal probe. Neither clone contained the SpeIo rXhoI sites, as
demonstrated by the presence of the 4.0 kb band in all lanes,
indicating recombination had occurred between the short 0.3 kb
PbCS 39 UTR sequence upstream of the marker cassette. A
second band in the transgenic parasite DNA of 2.0 kb, compared
to the 1.5 kb band in the Pbwt DNA, indicated the insertion of the
TgDHFR/TS cassette in the PbCS locus.
(TIF)
Figure S3 Sporozoite CSP expression and motility.
Confocal immunofluorescence microphotographs of P. berghei wt
and transgenic midgut sporozoites incubated at 37uC to induce
motility and developed with either a monoclonal antibody directed
against the PbCSP repeat region (Pb-RR), a serum directed
against the PgCSP N-terminal region (Pg-Nt), or a serum directed
against the PgCSP repeat region (Pg-RR). Sporozoites shed trails
of material recognised by antibody against the PbCSP repeat
region. Antibody against the PgCSP N-terminal region (Pg-Nt)
revealed mainly an intracellular pattern of expression, and no
trails, for the PgCS/Pb
RR, PgCS
SX and PgCS replacement
parasites. The antibody against the Pg-RR revealed the presence
of clumps of immunoreactive material either outside the parasite
body or in proximity to its surface.
(TIF)
Figure S4 Salivary gland sporozoite CSP expression and
motility. Confocal immunofluorescence microphotographs of P.
berghei wt and transgenic salivary gland sporozoites incubated at
either room temperature (RT) or 37uC and developed with an
antibody directed against the PbCSP repeat region (Pb-RR). The
antibody revealed surface expression in PbCS
DHFR and PbCS/
Pg
CT salivary gland sporozoites, similar to P. berghei wt salivary
gland sporozoites. Sporozoites incubated at 37uC shed trails of
material recognised by the anti-PbCSP repeat region antibody.
(TIF)
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